Not yet recruiting
Multimodal Ablation Combined With Perioperative Tislelizumab and Chemotherapy for Resectable II-IIIB NSCLC
NCT07729670
- Conditions
- NSCLC
- Locations
-
Not specified
Clinical trial condition
NSCLC
Explore clinical trials studying NSCLC. Study availability and eligibility vary by location and protocol.
367 public trials
125 recruiting studies
NSCLC trial results
Not yet recruiting
Imaging Study in Metastatic UC, HR+ and HER2- Breast Cancer, TNBC, and NSCLC
NCT07671092
- Conditions
- Breast Cancer, Breast Diseases, Breast Neoplasms, +21 more
- Locations
-
- Research Facility Christchurch, New Zealand
Not yet recruiting
A Phase Ib Study of Tislelizumab Plus SYS6010 in Immunotherapy-Pretreated Locally Advanced or Metastatic NSCLC
NCT07692048
- Conditions
- NSCLC
- Locations
-
- West China Hospital, Sichuan University Chengdu, Please Select, China
Not yet recruiting
An Open-label, Fixed-sequence Phase I Clinical Trial to Evaluate the Effect of HS-10504 on the Pharmacokinetics of Midazolam in Patients With Non-small Cell Lung Cancer
NCT07685041
- Conditions
- NSCLC
- Locations
-
Not specified
Not yet recruiting
Comparative ¹⁸F-FDG and ⁶⁸Ga-MY6349 PET/CT Imaging for Assessing TROP2 ADC Therapeutic Efficacy in EGFR-TKI Resistant Advanced NSCLC
NCT07685197
- Conditions
- EGFR Activating Mutation, EGFR-TKI-resistant Non-Small Cell Lung Cancer, NSCLC, +2 more
- Locations
-
Not specified
Not yet recruiting
The Efficacy and Safety of Trastuzumab Deruxtecan in Advanced or Metastatic NSCLC With HER2 Over Expression
NCT07662473
- Conditions
- NSCLC
- Locations
-
Not specified
Not yet recruiting
Toripalimab Combined With Platinum-based Chemotherapy With or Without H1 Receptor Antagonist in the Perioperative Treatment of Resectable Non-small Cell Lung Cancer
NCT07358689
- Conditions
- NSCLC
- Locations
-
- Tianjin Medical University Cancer Institute & Hospital Tianjin, China
NCT07643350
- Conditions
- NSCLC
- Locations
-
- ThirdXiangyaHCSU Changsha, Hunan, China
Not yet recruiting
Firmonertinib in Perioperative Treatment of Resectable Stage II-IIIB EGFR-mutated Lung Adenocarcinoma
NCT07622706
- Conditions
- EGFR Positive Non-small Cell Lung Cancer, NSCLC, Neoadjuvant Therapy
- Locations
-
Not specified
Not yet recruiting
A Phase Ⅲ Clinical Study of SYS6010 in Combination With Osimertinib in Patients With Locally Advanced or Metastatic NSCLC
NCT07376382
- Conditions
- NSCLC
- Locations
-
Not specified